The staff at the Institute for Clinical and Economic Review, also known as ICER, are often seen as the nerds of the drug industry. They are seen as bespectacled individuals who appear a few times a year to criticize drugmakers for pricing their latest cancer or MS treatments at exorbitant prices. However, last year, the ICER staff surprised everyone by concluding that a forthcoming treatment was worth up to $3.9 million. This valuation made it the most expensive medicine in history, surpassing the cost of 45 years’ worth of Humira, a commonly used autoimmune drug associated with high drug prices in America.
This valuation represented the tremendous potential of a new class of gene therapies to achieve something that pharmaceutical companies rarely do: provide genuine cures. The treatment, now approved as Lenmeldy, has the capability to allow babies born with the rare neurodegenerative disease known as metachromatic leukodystrophy (MLD) to live essentially normal lives. This breakthrough demonstrates the power of gene therapies to deliver life-changing treatments for rare and debilitating conditions, offering hope to patients and their families facing these challenges.
Jasmine Wong, a senior at Iolani School, made history by becoming the first individual champion…
Days before Iran's attack on Israel last month with more than 300 drones and missiles,…
Results from the Opal trial have shown promising results, with the potential for a cure…
Jamie Chacon, a 44-year-old man from Petersburg, is facing charges of rape and forcible sodomy…
The Fairbanks area faces challenges when it comes to navigating the aging process. In celebration…
Denver Nuggets star center Nikola Jokić was named the NBA’s Most Valuable Player on Wednesday…